2019 Event Summary

A Who's Who of AI in Biopharma

 

Key Takeaways

1. The passionate discussion and debate during the two days of the Summit made it clear that the adoption of AI tools is continuing at a fast pace and everyone attending is laser focused on driving progress to provide critical treatments to patients faster.

2. Talent management continues to be a key issue and speakers shared their thoughts about how to tackle today’s challenges in hiring and retaining critical staff. One speaker summed up the general consensus that, “It’s not about the sheer number of data scientists, it’s about the right people in the right place and incentivized in the right way.” The group also agreed that pharma has a noble mission that people are attracted to and this needs to be emphasized more to compete for talent effectively.

3. Data management and RWD were top of mind for many attendees. Valuable information was presented by the FDA providing an update on FDA’s real-world evidence program. The topics of data access, data bias and data privacy are critical to get right as policy decisions are being put in place that will impact biopharma companies as well as patients.

4. Deep dive sessions discussed how AI is in fact delivering value today but that new business models will become a necessary path to survival and evolution. Key learnings from these sessions include:

· Focus on building the right thing, not just building things right;

· Prioritize projects using complexity vs. value to find “low hanging fruit”; and

· Execute POC/POV projects lean startup style and then use the learnings to scale up.

5. All agreed that getting AI right will result in making a remarkable impact that starts with data.

   

Attendee Snapshot

 

What Past Attendees Say

 

"I have now attended the event consecutively over the last two years. On both occasions, I had an engaging dialogue on the enormous potential of AI to disrupt the clinical trials space. One-on-one expert meetings have been thought provoking. I love the diversity of the industry participants. We have had so much to learn from one another" - Nitin Naik, Global Vice President, Head-Life Sciences Practice, Frost & Sullivan

 

"The AI Applications in Biopharma Summit was an excellent experience where various industry and non-industry stakeholders engaged in honest and thoughtful discussion. The value of the Summit is that it convenes the right people for information sharing and thoughtful discussion to move the industry forward on the way to providing more efficient processes and better health outcomes." - Ijah Mondesire-Crump, MD, Director of Clinical Research, nQ Medical, Inc.

 

"The Summit is a fantastic overview of some of the things that are going on in the artificial intelligence field in relation to things like drug development, improving clinical trials, gathering real world evidence and dealing with the regulatory agencies in different parts of the world. The discussions are of high value and you always leave with new contacts and new information." - Ronald Dorenbos, Head Innovation Management & Scouting, Takeda (views expressed are Ron's and not the views or opinions of Takeda)

 

Event Gallery

AIApps 2019 - Deep Dive

AIApps 2019 - Jennifer

AIApps 2019 - Panelist

Deep Dive sessions covering Clinical Development, Discovery, and Data Democratization & Interoperability added a new important element of engagement and information sharing

Jennifer Pai, ScD, Merck & Co., Inc. led the discussion as session moderator

Session Panelists: Bolan Linghu, Ph.D., AstraZeneca - Niven Narain, Ph.D., BERG - M. Khair ElZarrad, Ph.D., MPH, FDA

 

AIApps 2019 - FDA

AIApps 2019 - Sponsor

AIApps 2019 - 121

M. Khair ElZarrad, Ph.D., MPH, Deputy Director, Office of Medical Policy, CDER, FDA gave an update on the FDA’s Real-World Evidence Program

Sponsor Reserved Tables for conversation and making connections

Expert one-to-one meetings run throughout the Summit

 

Register Your Interest for 2020 View 2019 Agenda

 

Attendee Companies Included

2019 companies